Tests melatonin for sleep and thinking in people with cirrhosis and hepatic encephalopathy
Tests nightly melatonin against thiamine for sleep and thinking in adults with cirrhosis.
Key facts
- Who runs it
- Weill Medical College of Cornell University
- Where
- New York, United StatesSee the site
- Trial code
- Registry title
- Affect of Melatonin on Sleep and Cognition in Cirrhosis
- Status
- Recruiting
- People taking part
- 18 people, planned
- Started
- 5 Aug 2025
- Expected to end
- 31 Dec 2026
- Type of study
- Interventional, 2 groups
- Treatments tested
- Melatonin tablet 3 mg once daily
- Thiamine
- Record updated
- 29 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with cirrhosis and hepatic encephalopathy (or mild, hidden confusion from liver disease) who sleep badly. It tests melatonin against thiamine.
- Age
- Adults over age 18
- Sex
- All sexes can join
- Disease stage
- Cirrhosis with significant portal hypertension or decompensation (Baveno VII criteria); covert hepatic encephalopathy (PHES ≤ -4) or earlier diagnosed hepatic encephalopathy
- Earlier treatment
- People who regularly take melatonin 3 times a week must be able and willing to stop it for the study
- Biomarker or test result
- Disturbed sleep with a Pittsburgh Sleep Quality Index (PSQI) score of 5 or more
Main reasons for not taking part
- Cannot give informed consent
- Heavy current alcohol use (more than 7 drinks a week for women, 14 for men)
- Body mass index over 40
- Known sleep disorder, including obstructive sleep apnea
- Pregnancy reported at screening
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Cirrhosis with clinically significant portal hypertension or decompensation defined by Baveno VII criteria [de Franchis R et al 2022]
- Adults over age 18
- CHE (defined by PHES≤ -4) or previously diagnosed HE
- Disturbed sleep, with Pittsburgh Sleep Quality Index (PSQI) ≥5
- Possession of a "smart phone" with Bluetooth capability and ability to download the Oura application (Apple iOS version 14.0 or greater or Android version 8.0 or higher)
Who cannot take part
- Known prior sleep disorder including obstructive sleep apnea
- Use of melatonin regularly (3x per week) if unable/unwilling to discontinue for the study
- Inability provide informed consent
- Heavy current alcohol use (>7 drinks weekly for women and 14 drinks weekly for men)'; -- Body mass index >40
- Use of other prescription neuromodulating sleep aides
- Self-reported pregnancy during study screening, as sleep physiology is different in this population
Where in United States
- NewYork-Presbyterian Weill Cornell Medical CenterNew York, United StatesContact: Adam P Buckholz, MD MSTaking people
About the trial
What the trial wants to find out
The goal of this clinical trial is to learn the affect of melatonin on sleep, cognitive function, and quality of life (QoL) in patients with cirrhosis and a complication called hepatic encephalopathy (HE). The main questions this study aims to answer are:
Read full original descriptionShow less
* Does taking melatonin increase REM sleep, an important part of healthy sleep that is reduced in cirrhosis? * Does taking melatonin improve cognitive function and reported QoL?
This is a pilot study, where participants will:
* take one month of melatonin, followed by one month of thiamine, which is another supplement but is not suspected to impact sleep significantly. * Undergo cognitive testing and take surveys * Wear a commercial wearable sleep tracker * Have a formal sleep study and salivary melatonin collection at the end of taking each supplement at our sleep center Participants will be blinded, and neither they nor the researchers will know which supplement they are taking first and which they are taking second. They will also be randomized, with half starting with melatonin and the other half starting with thiamine.
The 2 groups in the trial
- Melatonin then ThiamineTreatment being tested
This group will take one month of melatonin, followed by a one week washout period, then one month of thiamine. They will have the primary outcomes assessed at each month, and will also undergo continuous sleep monitoring via a wearable tracker during all phases of the arm.
Treatment: Melatonin tablet 3 mg once daily and Thiamine
- Thiamine then melatoninTreatment being tested
This group will take one month of melatonin, followed by a one week washout period, then one month of thiamine. They will have the primary outcomes assessed at each month, and will also undergo continuous sleep monitoring via a wearable tracker during all phases of the arm.
Treatment: Melatonin tablet 3 mg once daily and Thiamine
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Effect of Supplemental Nightly Melatonin On REM and Cognition in Hepatic Encephalopathy (SNORE-HE) Trial
- Plain-language title
- Tests melatonin for sleep and thinking in people with cirrhosis and hepatic encephalopathyGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 29 July 2026